Protein AF-9 (MLLT3) Antibody

Product Graph
312€ (60 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Protein AF-9 (MLLT3) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx006627
tested applications
WB

Description

MLLT3 Antibody is a Rabbit Polyclonal Antibody against MLLT3.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Protein AF-9 (MLLT3)
Host
Rabbit
Reactivity
Human, Mouse, Rat
Recommended Dilution
WB: 1/500 - 1/2000. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Isotype
IgG
Purification
Purified by affinity chromatography.
Size 1
60 µl
Size 2
120 µl
Size 3
200 µl
Form
Liquid
Tested Applications
WB
Buffer
PBS, pH 7.3, containing 0.01% thiomersal, 50% glycerol.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P42568
Gene ID
4300
NCBI Accession
NP_004520.2
Background
Antibody anti-MLLT3
Status
RUO
Note
Concentration: 1 mg/ml -

Descripción

Related Products

FNab00191

MLLT3 antibody

Ver Producto
abx006627

Protein AF-9 (MLLT3) Antibody

MLLT3 Antibody is a Rabbit Polyclonal Antibody against MLLT3.

Ver Producto
abx032720

Protein AF-9 (MLLT3) Antibody

The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t (9;11) (p22;q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified; BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.

Ver Producto